*Experimental Model of Cardiotoxicity DOI: http://dx.doi.org/10.5772/intechopen.101401*

[59] Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hospital Practice. 2019;**47**(1):6-15. DOI: 10.1080/21548331.2018.1530831. Epub 2018 ANTIPSYCHOTICMID: 30270693

[60] Herman EH, Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemotherapy and Pharmacology. 1986;**16**(2):102-106. DOI: 10.1007/BF00256157

[61] Zhang YY, Yi M, Huang YP. Oxymatrine ameliorates doxorubicininduced cardiotoxicity in rats. Cellular Physiology and Biochemistry. 2017;**43**(2):626-635. DOI: 10.1159/ 000480471. Epub 2017 Sep 21

[62] Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D, Lekli I, et al. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy. Molecules. 2018;**23**(5):1184. DOI: 10.3390/ molecules23051184

[63] Taşkıran E, Erdoğan MA, Yiğittürk G, Erbaş O. Therapeutic effects of liraglutide, oxytocin and granulocyte colony-stimulating factor in doxorubicin-induced cardiomyopathy model: An experimental animal study. Cardiovascular Toxicology. 2019; **19**(6):510-517. DOI: 10.1007/s12012- 019-09524-x

[64] Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/ imatinib mesilate combination in rats. The Journal of Pharmacy and Pharmacology. 2006;**58**(4):567-573. DOI: 10.1211/ jpp.58.4.0017

[65] Saleh RM, Awadin WF, El-Shafei RA, Elseady YY, Wehaish FE, Elshal MF. Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. European Journal of Pharmacology. 2015;**765**:574-581. DOI: 10.1016/j.ejphar.2015.09.015. Epub 2015 Sep 14

[66] Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, Franco VI, et al. Cardiotoxicity and cardioprotection in childhood cancer. Acta Haematologica. 2014;**132**(3-4): 391-399

[67] Gianfaldoni S, Gianfaldoni R, Wollina U, Lotti J, Tchernev G, Lotti T. An overview on radiotherapy: From its history to its current applications in dermatology. Open Access Macedonian Journal of Medical Sciences. 2017;**5**(4): 521-525

[68] Ell P, Martin JM, Cehic DA, Ngo DTM, Sverdlov AL. Cardiotoxicity of radiation therapy: Mechanisms, management, and mitigation. Current Treatment Options in Oncology. 2021;**22**(8):70

[69] Wei T, Cheng Y. The cardiac toxicity of radiotherapy—A review of characteristics, mechanisms, diagnosis, and prevention. International Journal of Radiation Biology. 2021;**97**:1-8

[70] Yi P, Li H, Fang Y, Su J, Xu C, Cao L, et al. Administration of trastuzumab with heart irradiation induced acute cardiotoxicity in mice. American Journal of Cancer Research. 2020;**10**(2):536-544

[71] Koczwara B, Meng R, Miller MD, Clark RA, Kaambwa B, Marin T, et al. Late mortality in people with cancer: A population-based Australian study. The Medical Journal of Australia. 2021;**214**(7):318-323. DOI: 10.5694/ mja2.50879. Epub 2020 Dec 9

[72] Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiationassociated cardiovascular disease. Critical Reviews Oncology Hematologyl. 2003 Jan;**45**(1):55-75. DOI: 10.1016/s1040- 8428(01)00227-x

[73] Ratosa I, Ivanetic PM. Cardiotoxicity of mediastinal radiotherapy. Reports of Practical Oncology and Radiotherapy. 2019;**24**(6):629-643. DOI: 10.1016/j. rpor.2019.09.002. Epub 2019 Oct 30

[74] Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;**135**(15): 1388-1396

[75] Frankart AJ, Nagarajan R, Pater L. The impact of proton therapy on cardiotoxicity following radiation treatment. Journal of Thrombosis and Thrombolysis. 2021;**51**(4):877-883

[76] Hoppe BS, Flampouri S, Su Z, Latif N, Dang NH, Lynch J, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics. 2012;**84**(2):449-455

[77] Giraud P, Cosset JM. Toxicité cardiaque de la radiothérapie: physiopathologie, données cliniques [Radiation toxicity to the heart: Physiopathology and clinical data]. Bulletin du Cancer. 2004;**91**(Suppl 3):147-153. French

[78] Yusuf SW, Venkatesulu BP, Mahadevan LS, Krishnan S. Radiationinduced cardiovascular disease: A clinical perspective. Frontiers in Cardiovascular Medicine. 2017;**4**:66

[79] Elkady AA, Mohamed ET. Possible role of Withania somnifera against gamma radiation induced cardiotoxicity in male albino rats. Pakistan Journal of Zoology. 2016;**48**(2):539-545

[80] Mohamed ET, Elkady AA, Mohamed S, Said E, Kiki E. Protective effect of Symplocos racemosa Roxb against gamma radiation induced cardiotoxicity in male albino rats. Pakistan Journal of Zoology. 2016;**48**(6):1831-1837

[81] Mansour HH, Eid M, El-Arnaouty MB. Effect of silver nanoparticles synthesized by gamma radiation on the cytotoxicity of doxorubicin in human cancer cell lines and experimental animals. Human & Experimental Toxicology. 2018;**37**(1): 38-50

[82] EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;**383**(9935):2127-2135. DOI: 10.1016/ S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848

[83] Mezzaroma E, Di X, Graves P, Toldo S, Van Tassell BW, Kannan H, et al. A mouse model of radiation-induced cardiomyopathy. International Journal of Cardiology. 2012;**156**(2):231-233. DOI: 10.1016/j.ijcard.2012.01.038. Epub 2012 Feb 16

[84] Boerma M, Wang J, Wondergem J, Joseph J, Qiu X, Kennedy RH, et al. Influence of mast cells on structural and functional manifestations of radiationinduced heart disease. Cancer Research. 2005;**65**(8):3100-3107. DOI: 10.1158/ 0008-5472.CAN-04-4333

[85] Dreyfuss AD, Goia D, Shoniyozov K, Shewale SV, Velalopoulou A, Mazzoni S, et al. A novel mouse model of radiationinduced cardiac injury reveals biological and radiological biomarkers of cardiac dysfunction with potential clinical relevance. Clinical Cancer Research. 2021;**27**(8):2266-2276. DOI: 10.1158/1078- 0432.CCR-20-3882. Epub 2021 Feb 4

[86] Ibrahim EH, Baruah D, Croisille P, Stojanovska J, Rubenstein JC, Frei A, et al. Cardiac magnetic resonance for early detection of radiation therapy-induced cardiotoxicity in a small animal model.

*Experimental Model of Cardiotoxicity DOI: http://dx.doi.org/10.5772/intechopen.101401*

JACC: CardioOncology. 2021;**3**(1):113- 130. DOI: 10.1016/j.jaccao.2020.12.006. Epub 2021 Mar 16

[87] Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T. Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Seminars in Cardiothoracic and Vascular Anesthesia. 2012;**16**(3):123-132

[88] Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncologica. 1990;**29**(8): 1001-1003

[89] Pagliaro BR, Cannata F, Stefanini GG, Bolognese L. Myocardial ischemia and coronary disease in heart failure. Heart Failure Reviews. 2020; **25**(1):53-65

[90] Allawadhi P, Khurana A, Sayed N, Kumari P, Godugu C. Isoproterenolinduced cardiac ischemia and fibrosis: Plant-based approaches for intervention. Phytotherapy Research. 2018;**32**(10): 1908-1932

[91] Oun R, Rowan E. Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? European Journal of Pharmacology. 2017;**811**: 125-128

[92] Tunio MA, Hashmi A, Shoaib M. Capecitabine induced cardiotoxicity: A case report and review of literature. Pakistan Journal of Pharmaceutical Sciences. 2012;**25**(1):277-281

[93] McGoldrick TA, Jodrell D, Clive S. Capecitabine (oral 5-fluorouracil prodrug) treatment for colorectal carcinoma causing ischaemic chest pain. BML Case Reports. 2009;**2009**:bcr07.2008.0449

[94] Bursac D. Myocardial ischemia during combined chemotherapy with etoposide and cisplatin for non-small lung cancer. Oncology & Cancer Case Reports. 2018;**4**:141

[95] Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology. 2015;**309**(9):H1453-H1467

[96] Alamolhodaei NS, Shirani K, Karimi G. Arsenic cardiotoxicity: An overview. Environmental Toxicology and Pharmacology. 2015;**40**(3):1005-1014

[97] Lamberti M, Giovane G, Garzillo EM, Avino F, Feola A, Porto S, et al. Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers. BioMed Research International. 2014;**2014**:240642

[98] Shao H, Dong L, Feng Y, Wang C, Tong H. The protective effect of L-glutamine against acute cantharidininduced cardiotoxicity in the mice. BMC Pharmacology and Toxicology. 2020;**21**(1):71

[99] Akinmoladun AC, Obuotor EM, Barthwal MK, Dikshit M, Farombi EO. Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart. Cardiovascular Toxicology. 2010;**10**(4):295-305

[100] Jain PG, Mahajan UB, Shinde SD, Surana SJ. Cardioprotective role of FA against isoproterenol induced cardiac toxicity. Molecular Biology Reports. 2018;**45**(5):1357-1365

[101] Li XL, Chen LY, Guan ZY, Luo Y, Cui YR, Liu RH, et al. Effect of neoflavonoid latifolin isolated from Dalbergia odorifera on acute myocardial ischemia in rats and its mechanism of Nrf2 signaling pathway. Zhongguo Zhong Yao Za Zhi. 2017;**42**(20):3974-3982. Chinese. DOI: 10.19540/j.cnki. cjcmm.20170907.009

[102] Zhang N, Shou B, Chen L, Lai X, Luo Y, Meng X, et al. Cardioprotective effects of latifolin against doxorubicininduced cardiotoxicity by macrophage polarization in mice. Journal of Cardiovascular Pharmacology. 2020;**75**(6):564-572

[103] Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Lancet. 2014;**383**(9922): 1084-1094

[104] Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;**20**(5):853-872

[105] Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, et al. Distinct pathological pathways in patients with heart failure and diabetes. JACC: Heart Failure. 2020;**8**:234-242

[106] DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. The Journal of Biological Chemistry. 2006;**281**(43):32841-32851

[107] Riehle C, Abel ED. Insulin signaling and heart failure. Circulation Research. 2016;**118**(7):1151-1169

[108] Eijkelenboom A, Burgering BM. FOXOs: Signalling integrators for homeostasis maintenance. Nature Reviews. Molecular Cell Biology. 2013;**14**(2):83-97

[109] Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Failure Reviews. 2002;**7**:115-130

[110] Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. The American Journal of Medicine. 2008;**121**(9):748-757

[111] Schilling JD, Mann DL. Diabetic cardiomyopathy: Bench to bedside. Heart Failure Clinics. 2012;**8**(4):619-631

[112] Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Research in Cardiology. 2007;**102**(6):500-507. DOI: 10.1007/ s00395-007-0673-0. Epub 2007 Oct 5

[113] Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;**53**(8):2079-2086

[114] Kaur N, Guan Y, Raja R, Ruiz-Velasco A, Liu W. Mechanisms and therapeutic prospects of diabetic cardiomyopathy through the inflammatory response. Frontiers in Physiology. 2021;**21**(12):694864

[115] Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochemical Pharmacology. 2019;**170**:113677

[116] Çavuşoğlu T, Çiftçi ÖD, Çağıltay E, Meral A, Kızıloğlu İ, Gurgul S, et al. Histological and biochemical examination of the effect of oxytocin on diabetic cardiomyopathy rat model. Dicle Medical Journal. 2017;**44**(2):135-143

[117] Broderick TL, Hutchison AK. Cardiac dysfunction in the euglycemic diabetic-prone BB Wor rat. Metabolism. 2004;**53**(11):1391-1394

## *Experimental Model of Cardiotoxicity DOI: http://dx.doi.org/10.5772/intechopen.101401*

[118] Jain A, Rani V. Curcumin-mediated effects on anti-diabetic drug-induced cardiotoxicity. 3 Biotech. 2018;**8**(9):399

[119] Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;**75**(10):1071-1094

[120] Kobashigawa LC, Xu YC, Padbury JF, Tseng YT, Yano N. Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: An in vitro study. PLoS ONE. 2014;**9**(8):e104888

[121] Asensio-López MC, Lax A, Pascual-Figal DA, Valdés M, Sánchez-Más J. Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system. Free Radical Biology & Medicine. 2011;**51**(10):1861-1871

[122] Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;**60**(9):1577-1585. DOI: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3

[123] Smith U. Pioglitazone: Mechanism of action. International Journal of Clinical Practice. Supplement. 2001;**121**:13-18

[124] Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiology Research and Practice. 2014;**2014**:273060. DOI: 10.1155/2014/273060. Epub 2014 Feb 4

[125] Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety. 2000;**23**(3):215-228. DOI: 10.2165/00002018-200023030-00004

[126] Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic

inhibition. Journal of Clinical Psychopharmacology. 2004;**24**(1):62-69. DOI: 10.1097/01.jcp.0000104913.75206.62

[127] Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;**354**(9193): 1841-1845. DOI: 10.1016/s0140- 6736(99)10385-4

[128] Schneider J, Patterson M, Jimenez XF. Beyond depression: Other uses for tricyclic antidepressants. Cleveland Clinic Journal of Medicine. 2019;**86**(12):807-814. DOI: 10.3949/ ccjm.86a.19005

[129] Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. International Journal of Molecular Sciences. 2017;**18**(11):2483. DOI: 10.3390/ijms18112483

[130] Moraczewski J, Aedma KK. Tricyclic Antidepressants. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. p. 2021. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK557791/

[131] Foianini A, Joseph Wiegand T, Benowitz N. What is the role of lidocaine or phenytoin in tricyclic antidepressantinduced cardiotoxicity? Clinical Toxicology (Philadelphia, Pa.). 2010;**48**(4):325-330. DOI: 10.3109/ 15563650.2010.487050

[132] Bateman DN, Chick J, Good AM, Kelly CA, Masterton G. Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose? European Jouirnal of Clinical Pharmacology. 2004;**60**(3):221-224. DOI: 10.1007/s00228-004-0748-x

[133] Bora S, Erdoğan MA, Yiğittürk G, Erbaş O, Parlak İ. The effects of lipid emulsion, magnesium sulphate and metoprolol in amitriptyline-induced cardiovascular toxicity in rats.

Cardiovascular Toxicology. 2018;**18**(6): 547-556. DOI: 10.1007/s12012-018- 9466-y

[134] Erbas O, Yilmaz M. Metoprolol and diltiazem ameliorate ziprasidoneinduced prolonged corrected QT interval in rats. Toxicology and Industrial Health. 2015;**31**(12):1152- 1157. DOI: 10.1177/0748233713487249. Epub 2013 Apr 26

[135] Abdel-Wahab BA, Metwally ME. Clozapine-induced cardiotoxicity in rats: Involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicology Reports. 2014;**1**:1213-1223. DOI: 10.1016/j.toxrep.2014.11.012

[136] Chadwick AC, Musunuru K. Genome editing for the study of cardiovascular diseases. Current Cardiology Reports. 2017;**19**(3):22. DOI: 10.1007/s11886-017-0830-5

[137] Christidi E, Huang HM, Brunham LR. CRISPR/Cas9-mediated genome editing in human stem cellderived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening. Drug Discovery Today: Technologies. 2018;**28**:13-21. DOI: 10.1016/j.ddtec.2018.06.002. Epub 2018 Jun 25

[138] Wang Y, Liang P, Lan F, Wu H, Lisowski L, Gu M, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. Journal of the American College of Cardiology. 2014;**64**(5):451-459. DOI: 10.1016/j. jacc.2014.04.057

[139] Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. The New England Journal of Medicine. 2010;**363**(15):1397-1409. DOI: 10.1056/NEJMoa0908679. Epub 2010 Jul 21

[140] Ma D, Wei H, Lu J, Huang D, Liu Z, Loh LJ, et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Research & Therapy. 2015;**6**(1):39. DOI: 10.1186/ s13287-015-0027-z

[141] Yamamoto Y, Makiyama T, Harita T, Sasaki K, Wuriyanghai Y, Hayano M, et al. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation. Human Molecular Genetics. 2017;**26**(9):1670-1677. DOI: 10.1093/ hmg/ddx073

[142] Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal. 2011;**32**(8):952-962. DOI: 10.1093/ eurheartj/ehr073. Epub 2011 Mar 2

[143] Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. The EMBO Journal. 2013;**32**(24):3161-3175. DOI: 10.1038/ emboj.2013.240. Epub 2013 Nov 8

[144] Mehta A, Sequiera GL, Ramachandra CJ, Sudibyo Y, Chung Y, Sheng J, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovascular Research. 2014;**102**(3): 497-506. DOI: 10.1093/cvr/cvu060. Epub 2014 Mar 12

[145] Terrenoire C, Wang K, Tung KW, Chung WK, Pass RH, Lu JT, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. *Experimental Model of Cardiotoxicity DOI: http://dx.doi.org/10.5772/intechopen.101401*

The Journal of General Physiology. 2013;**141**(1):61-72. DOI: 10.1085/ jgp.201210899

[146] Spencer CI, Baba S, Nakamura K, Hua EA, Sears MA, Fu CC, et al. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Reports. 2014;**3**(2):269-281. DOI: 10.1016/j.stemcr.2014.06.003. Epub 2014 Jul 4

[147] Limpitikul WB, Dick IE, Tester DJ, Boczek NJ, Limphong P, Yang W, et al. A precision medicine approach to the rescue of function on malignant calmodulinopathic long-QT syndrome. Circulation Research. 2017;**120**(1):39- 48. DOI: 10.1161/CIRCRESAHA. 116.309283. Epub 2016 Oct 20

[148] Stokoe KS, Balasubramaniam R, Goddard CA, Colledge WH, Grace AA, Huang CL. Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/− murine hearts modelling the Brugada syndrome. The Journal of Physiology. 2007;**581**(Pt 1):255-275. DOI: 10.1113/jphysiol.2007.128785. Epub 2007 Feb 15

[149] Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, Benndorf K, et al. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proceedings of the National Academy of Sciences of the United States of America. 2002;**99**(9):6210-6215. DOI: 10.1073/pnas.082121299. Epub 2002 Apr 23

[150] Liang P, Sallam K, Wu H, Li Y, Itzhaki I, Garg P, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada Syndrome. Journal of the American College of Cardiology. 2016;**68**(19):2086-2096. DOI: 10.1016/j. jacc.2016.07.779

[151] Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. Journal of the American College of Cardiology. 2012;**60**(11):990-1000. DOI: 10.1016/j. jacc.2012.02.066. Epub 2012 Jun 27

[152] Rajan S, Ahmed RP, Jagatheesan G, Petrashevskaya N, Boivin GP, Urboniene D, et al. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circulation Research. 2007;**101**(2):205-214. DOI: 10.1161/ CIRCRESAHA.107.148379. Epub 2007 Jun 7. Erratum in: Circ Res. 2007 Sep 14;101(6):e80

[153] Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Science Translational Medicine. 2012;**4**(130):130ra47. DOI: 10.1126/scitranslmed.3003552

[154] Li S, Mo K, Tian H, Chu C, Sun S, Tian L, et al. Lmod2 piggyBac mutant mice exhibit dilated cardiomyopathy. Cell & Bioscience. 2016;**6**:38. DOI: 10.1186/s13578-016-0101-y

[155] Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circulation Research. 2007;**101**(2):185-194. DOI: 10.1161/ CIRCRESAHA.106.146670. Epub 2007 Jun 7

[156] Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;**349**(6251):982-986. DOI: 10.1126/science.aaa5458

[157] Vikstrom KL, Factor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Molecular Medicine. 1996;**2**(5):556-567

[158] Ferrantini C, Coppini R, Pioner JM, Gentile F, Tosi B, Mazzoni L, et al. Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: A comparison of the cardiac troponin T E163R and R92Q mouse models. Journal of the American Heart Association. 2017;**6**(7):e005407. DOI: 10.1161/JAHA.116.005407

[159] Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, et al. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. The Journal of Clinical Investigation. 1999;**104**(4):469-481. DOI: 10.1172/ JCI6067

[160] Moore RK, Abdullah S, Tardiff JC. Allosteric effects of cardiac troponin TNT1 mutations on actomyosin binding: A novel pathogenic mechanism for hypertrophic cardiomyopathy. Archives of Biochemistry and Biophysics. 2014;**552-553**:21-28. DOI: 10.1016/j. abb.2014.01.016. Epub 2014 Jan 28

[161] Song W, Dyer E, Stuckey DJ, Copeland O, Leung MC, Bayliss C, et al. Molecular mechanism of the E99K mutation in cardiac actin (ACTC Gene) that causes apical hypertrophy in man and mouse. The Journal of Biological Chemistry. 2011;**286**(31):27582-27593. DOI: 10.1074/jbc.M111.252320. Epub 2011 May 26

[162] Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patientspecific induced pluripotent stem cells. Cell Stem Cell. 2013;**12**(1):101-113. DOI: 10.1016/j.stem.2012.10.010

[163] Huang F, Na N, Ijichi T, Wu X, Miyamoto K, Ciullo A, et al. Exosomally derived Y RNA fragment alleviates hypertrophic cardiomyopathy in transgenic mice. Molecular Therapy— Nucleic Acids. 2021;**24**:951-960. DOI: 10.1016/j.omtn.2021.04.014

[164] Mogensen J, Kubo T, Duque M, Uribe W, Shaw A, Murphy R, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation. 2003;**111**(2):209-216. DOI: 10.1172/JCI16336. Erratum in: The Journal of Clinical Investigation 2003 Mar;111(6):925

[165] Liu X, Zhang L, Pacciulli D, Zhao J, Nan C, Shen W, et al. Restrictive cardiomyopathy caused by troponin mutations: Application of disease animal models in translational studies. Frontiers in Physiology. 2016;**7**:629. DOI: 10.3389/fphys.2016.00629

[166] Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nature Communications. 2015;**6**:6955. DOI: 10.1038/ncomms7955

[167] Stillitano F, Turnbull IC, Karakikes I, Nonnenmacher M, Backeris P, Hulot JS, et al. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. European Heart Journal. 2016;**37**(43):3282-3284. DOI: 10.1093/ eurheartj/ehw307. Epub 2016 Jul 22

[168] Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;**548**(7668):413-419. DOI: 10.1038/ nature23305. Epub 2017 Aug 2
